Eupraxia PharmaceuticalsEPRX
13F holders, Q4 2024 (December 31)9holders +1
1new positions
1sold out
1famous investor
$3.09avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings, up 1 from Q3 2024. 1 opened new positions and 1 sold out. The largest holders were Scotia Capital Inc. ($4.3M), Royal Bank of Canada ($898K) and Bank of Montreal ($178K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $31K |
| Exits | 1 | $4K |
All 13F filers, Q3 2024 → Q4 2024: 29,358 shares bought and 13,669 shares sold, net +15,689 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Scotia Capital Inc. | 0.02% | Reduce -0.3% | 1,391,719 | $4.3M |
| Royal Bank of Canada | 0.00% | Add +4.4% | 283,145 | $898K |
| Bank of Montreal | 0.00% | Add +15.2% | 56,750 | $178K |
| Goldman Sachs Group Inc. | 0.00% | No change | 34,500 | $109K |
| UBS Group AG | 0.00% | Reduce -15.2% | 28,000 | $89K |
| Raymond James Financial Inc. | 0.00% | — | 11,613 | $37K |
| 180 Wealth Advisors, LLC | 0.01% | Reduce -19.2% | 10,500 | $33K |
| Millennium Management | 0.00% | New | 10,000 | $31K |
| National Bank of Canada | 0.00% | Reduce -71.3% | 43 | $135 |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.